Table 2.
Individual Patient's Clinical, Radiographic, Treatment, Histopathologic, and Survival Characteristics
| Patient | Location | Histology | Stage | Chemo | Preop Plts (×103) | Postop Plts (×103) | Time to chemo (days) | Status at last F/U | Diagnosis to surgery (months) | Survival from Dx (months) | Survival from surgery (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | H/U | PDAC | 3 | CiFU/LV+MitoC | 82 | 370 | 13 | DOD | 1.37 | 4.2 | 2.8 |
| 2 | H/U | PDAC | 3 | Gemzar | 96 | 555 | 6 | DOD | 38.3 | 48.2 | 40 |
| 3 | H/U | PDAC | 4 | GTX | 87 | 425 | 14 | DOD | 57 | 15.7 | 5.9 |
| 4 | H/U | PDAC | 3 | GTX | 86 | 321 | 14 | DOD | 57.03 | 67.2 | 9.4 |
| 5 | H/U | PDAC | 3 | GFLIP | 87 | 533 | 22 | AWD | 38.3 | 63.5 | 25.2 |
| 6 | B/T | PDAC | 4 | GFLIP | 81 | 403 | – | AWD | 4.4 | 17.9 | 13.4 |
| 7 | H/U | PDAC | 4 | CiFU/LV/MitoC/Persantine | 81 | 447 | 9 | DOD | 9.2 | 20.4 | 10.6 |
| 8 | B/T | PDAC | 3 | CiFU/LV/MitoC/Persantine | 91 | 361 | 20 | DOD | 9.3 | 11.2 | 1.9 |
| 9 | B/T | PET (well-diff.) | 4 | Temodar/Xeloda | 66 | 864 | 10 | AWD | 9.6 | 60.3 | 50.7 |
| 10 | H/U | PDAC | 3 | Gemzar | 113 | 300 | – | DOD | 10.3 | 20.4 | 10.1 |
| 11 | B/T | PET (well-diff.) | 4 | VP16/Cisplatin | 111 | 679 | 27 | DOD | 5.03 | 107 | 95.8 |
| 12 | H/U | PDAC | 3 | CiFU/LV/MitoC | 86 | 541 | – | DOD | 10.6 | 28.3 | 17.3 |
| 13 | B/T | PDAC | 4 | GTX | 88 | 994 | 8 | AWD | 2.2 | 34.9 | 32.7 |
| 14 | H/U | PDAC | 4 | GTX | 73 | 237 | 6 | DOD | 9.13 | 17.4 | 17.1 |
| 15 | B/T | PDAC | 4 | GTX | 160 | 229 | 11 | AWD | 4.05 | 13.3 | 0.67 |
H/U head or uncinate tumor, B/T body or tail, DOD died of disease, AWD alive with disease, CiFU continous infusion 5FU, LV leukovorin, MitoC mitomycin C, Gemzar gemcitabine, GFLIP gemcitabine + 5FU + leukovorin + irinotecan + persantine, Temodar temozolomide, GTX gemcitobine + taxotere